PRINCETON, N.J.— Dr. Reddy’s announced the launch of methylprednisolone sodium succinate for injection, USP, the generic equivalent of SOLU-MEDROL (methylprednisolone sodium succinate for injection, USP) in the U.S. Market approved by the U.S. Food and Drug Administration (USFDA).

The SOLU-MEDROL brand and generic had U.S. sales of approximately $144 million MAT for the most recent twelve months ending in February 2022 according to IQVIA Health.

Dr. Reddy’s methylprednisolone sodium succinate for injection, USP, is supplied in 40 mg/vial,125 mg/vial single-dose vials each carton containing 25 vials; 500 mg and 1 gm multi-dose vial each carton containing 1 vial.